Tuesday, February 19, 2013

Metastatic tumors best for sunitinib response evaluation in mRCC

When evaluating treatment response in non-nephrectomized patients with metastatic renal cell carcinoma, the primary lesion does not have to be selected as the target lesion, researchers report.

via Med Wire News

No comments:

Post a Comment